Skip to main content

Table 1 Baseline characteristics by CKD-stage

From: Temporal trends in treatment strategies and clinical outcomes among patients with advanced chronic kidney disease and ST-elevation myocardial infarctions: results from the Bremen STEMI registry

  CKD stage
G1 (n = 3370) G2 (n = 4005) G3a (n = 1212) G3b-G5 (n = 1018) Significance
Age (years ± SD) 54.9 ± 10 66.1 ± 12 71,8 ± 11 75.9 ± 11 < 0.01
Women (%) 19.5 26.4 38.6 46.4 < 0.01
Body mass index (BMI) (kg/m2 ± SD) 27.7 ± 5 27.5 ± 5 27.5 ± 5 27.2 ± 5 0.01
Diabetes (%) 16.2 17.6 24.9 29.8 < 0.01
Current smokers (%) 63.8 35.4 22.7 16.2 < 0.01
Arterial hypertension (%) 50.9 63.8 71.7 72.1 < 0.01
Medical history
 PCI (%) 9.4 12.8 15.5 14.8 < 0.01
 Acute myocardial infarction (%) 9.1 12.7 16.4 17.5 < 0.01
 CABG (%) 1.4 2.7 4.4 4.9 < 0.01
 Stroke/TIA (%) 3.0 5.9 8.4 10.1 < 0.01
Treatment strategy
 Primary PCI (%) 94.1 89.8 86.3 84.1 < 0.01
 Urgent/early elect. CABG (%) 3.0 5.3 7.4 7.5 < 0.01
 Conservative (%) 2.8 4.9 6.3 8.5 < 0.01
Systemic thrombolysis with (rescue) PCI (%) 1.1 2.1 4.5 4.2 < 0.01
Systemic thrombolysis (stand alone) (%) 0 0.15 0 0
Coronary vessels diseased
 1 (%) 45.6 36.2 29.5 21.7 < 0.01
 2 (%) 30.6 31.2 32.4 29.8 0.05
 3 (%) 23.7 32.6 38.1 48.5 < 0.01
Subacute STEMI (%) 11.1 12.6 12.4 13.8 0.02
Cardiogenic shock (%) 6.4 10.4 23.7 30.9 < 0.01
TIMI 0/1 flow after PCI (%) 2.6 4.5 7.1 10.6 < 0.01
Peak CK > 2000 U/l (%) 31.9 31.4 30.5 28.8 0.07
Creatine at admission (mg/dl ± SD) 0.75 ± 0.13 0.97 ± 0.15 1.23 ± 0.18 2.22 ± 4.15 < 0.01
eGFR at admission (ml/min ± SD) 101 ± 8.4 76.2 ± 8.6 53.2 ± 4.2 32.3 ± 10.0 < 0.01
Contrast media used (ml ± SD) 143.9 ± 61 146.5 ± 61 144.1 ± 63 144.6 ± 71 0.3
Contrast media > 150 ml (%) 33.3 35.8 34.9 36.4 0.06
Stent type
 Bare metal stent (%) 36.8 46.6 50.5 45.8 < 0.01
 Drug eluting stent (%) 59.3 47.5 41.1 44.1 < 0.01
 No stent (POBA) (%) 3.8 5.8 8.4 10.0 < 0.01
Medication at discharge
 ASS (%) 98.9 97.1 92.6 89.4 < 0.01
 Clopidogrel (%) 25.6 46.8 57.1 56.3 < 0.01
 Ticagrelor or prasugrel (%) 70.9 46.3 31.8 31.7 < 0.01
 Triple therapy (%) 8.4 12.2 16.2 12.6 < 0.01
 Statin (%) 95.5 89.2 78.3 68.1 < 0.01
 ACE-inhibitor/ATR (%) 90.3 82.1 70.4 55.8 < 0.01
 Betablocker (%) 77.8 80.4 75.7 64.5 < 0.01